Investing.com - Talis Biomedical (NASDAQ: TLIS) reported second quarter EPS of $-8.2700, $1.31 better than the analyst estimate of $-9.5800. Revenue for the quarter came in at $580K versus the consensus estimate of $102.5K.
Talis Biomedical's stock price closed at $7.5900. It is up 11.0900% in the last 3 months and down -36.3700% in the last 12 months.
Talis Biomedical saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Talis Biomedical's stock price’s past reactions to earnings here.
According to InvestingPro, Talis Biomedical's Financial Health score is "fair performance".
Check out Talis Biomedical's recent earnings performance, and Talis Biomedical's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar